A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors

Stemmer,Salomon  M.; Benjaminov,Ofer; Silverman,Michael  H.; Sandler,Uziel; Purim,Ofer; Sender,Naomi; Meir,Chen; Oren‑Apoteker,Pnina; Ohana,Joel; Devary,Yoram

doi:10.3892/mco.2017.1505

A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors

Authors:
- Salomon M. Stemmer
- Ofer Benjaminov
- Michael H. Silverman
- Uziel Sandler
- Ofer Purim
- Naomi Sender
- Chen Meir
- Pnina Oren‑Apoteker
- Joel Ohana
- Yoram Devary
View Affiliations

Affiliations: Davidoff Center, Rabin Medical Center, Institute of Oncology, Petah Tikva 49414, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel, Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel
Published online on: November 15, 2017 https://doi.org/10.3892/mco.2017.1505
Pages: 22-29
Copyright: © Stemmer et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present phase I first‑in‑human study was to investigate the safety/efficacy of dTCApFs (a novel hormone peptide that enters cells through the T1/ST2 receptor), in advanced/metastatic solid tumors. The primary objective of this open‑label dose‑escalation study was to determine the safety profile of dTCApFs. The study enrolled patients (aged ≥18 years) with pathologically confirmed locally advanced/metastatic solid malignancies, who experienced treatment failure or were unable to tolerate previous standard therapy. The study included 17 patients (64% male; median age, 65 years; 47% colorectal cancer, 29% pancreatic cancer). The patients received 1‑3 cycles of escalating dTCApFs doses (6‑96 mg/m2). The mean number ± standard deviation of treatment cycles/patient was 3.2±1.4; no dose‑limiting toxicities were observed up to a dose of 96 mg/m2, and the maximum tolerated dose was not reached. Half‑life, maximal plasma concentration, and dTCApFs exposure were found to be linearly correlated with dose. Five patients were treated for ≥3 months (12, 24, 48 mg/m2) and experienced stable disease throughout the treatment period, and 1 experienced pathological complete response. Analysis of serum biomarkers revealed decreased levels of angiogenic factors at dTCApFs concentrations of 12‑48 mg/m2, increased levels of anticancer cytokines, and induction of the endoplasmic reticulum (ER) stress biomarker GRP78/BiP. Efficacy and biomarker data suggest that patients whose tumors were T1/ST2‑positive exhibited a better response to dTCApFs. In conclusion, dTCApFs was found to be safe/well‑tolerated, and potentially efficacious, with linear pharmacokinetics. Consistent with preclinical studies, the mechanism through which dTCApFs exerts anticancer effects appears to involve induction of ER stress, suppression of angiogenesis, and activation of the innate immune response. However, further studies are warranted.

View Figures

View References

1	Sandler U, Devary O, Braitbard O, Ohana J, Kass G, Rubinstein AM, Friedman ZY and Devary Y: NEROFE-a novel human hormone-peptide with anti-cancer activity. J Exp Ther Oncol. 8:327–339. 2010.PubMed/NCBI
2	Marazzi A: Algorithms, routines and S functions for robust statistics: The FORTRAN library ROBETH with an interface to S-PLUS. Chapman and Hall; New York City, NY: 1993
3	Fox J: Applied regression analysis, linear models, and related methods. Sage Publications, Inc.; London, England: 1997
4	Saccani S, Polentarutti N, Penton-Rol G, Sims JE and Mantovani A: Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo. Cytokine. 10:773–780. 1998. View Article : Google Scholar : PubMed/NCBI
5	Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ and Cheresh DA: Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 6:3056–3061. 2000.PubMed/NCBI
6	Lu DP, Zhou XY, Yao LT, Liu CG, Ma W, Jin F and Wu YF: Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 14:1982014. View Article : Google Scholar : PubMed/NCBI
7	O'Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, O'Riordain M, Bennett MW, Brint E and Houston A: An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 114:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
8	Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K and Pauwels RA: Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest. 106:551–559. 2000. View Article : Google Scholar : PubMed/NCBI
9	Walzl G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw PJ and Hussell T: Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med. 193:785–792. 2001. View Article : Google Scholar : PubMed/NCBI
10	Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, Ottoson P, Persson P, Delaney T, Lehar S, et al: Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. 190:895–902. 1999. View Article : Google Scholar : PubMed/NCBI
11	Meisel C, Bonhagen K, Löhning M, Coyle AJ, Gutierrez-Ramos JC, Radbruch A and Kamradt T: Regulation and function of T1/ST2 expression on CD4+ T cells: Induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol. 166:3143–3150. 2001. View Article : Google Scholar : PubMed/NCBI
12	Xu D, Chan WL, Leung BP, Huang FP, Wheeler R, Piedrafita D, Robinson JH and Liew FY: Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 187:787–794. 1998. View Article : Google Scholar : PubMed/NCBI
13	Townsend MJ, Fallon PG, Matthews DJ, Jolin HE and McKenzie AN: T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 191:1069–1076. 2000. View Article : Google Scholar : PubMed/NCBI
14	Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S and Zaheer A: Alzheimer's disease: Evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 40:297–308. 2014.PubMed/NCBI
15	Van Elssen CH, Vanderlocht J, Frings PW, Senden-Gijsbers BL, Schnijderberg MC, van Gelder M, Meek B, Libon C, Ferlazzo G, Germeraad WT and Bos GM: Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells. Eur J Immunol. 40:3138–3149. 2010. View Article : Google Scholar : PubMed/NCBI
16	Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID and Skak K: IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 57:1439–1449. 2008. View Article : Google Scholar : PubMed/NCBI
17	Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA and Bielekova B: A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 17:604–609. 2011. View Article : Google Scholar : PubMed/NCBI
18	van de Laar L, Coffer PJ and Woltman AM: Regulation of dendritic cell development by GM-CSF: Molecular control and implications for immune homeostasis and therapy. Blood. 119:3383–3393. 2012. View Article : Google Scholar : PubMed/NCBI
19	Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL and Kita H: IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 123:1047–1054. 2009. View Article : Google Scholar : PubMed/NCBI
20	Nabekura T, Girard JP and Lanier LL: IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection. J Immunol. 194:5948–5952. 2015. View Article : Google Scholar : PubMed/NCBI
21	ClinicalTrials.gov, . Description of a trial investigating Interleukin-12 in ovarian epithelial cancer or primary peritoneal cancer. https://clinicaltrials.gov/ct2/show/NCT00016289?term=IL12p70&rank=7January 11–2017
22	ClinicalTrials.gov, . Description of the recombinant interleukin-21 in metastatic melanoma and kidney cancer. https://clinicaltrials.gov/ct2/show/NCT00095108?term=IL-21&rank=7January 11–2017
23	Vasudev NS and Reynolds AR: Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis. 17:471–494. 2014. View Article : Google Scholar : PubMed/NCBI
24	Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:404–407. 1997. View Article : Google Scholar : PubMed/NCBI
25	Jain RK: Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park). 19 4 Suppl 3:S7–S16. 2005.
26	Tahergorabi Z and Khazaei M: Imbalance of angiogenesis in diabetic complications: The mechanisms. Int J Prev Med. 3:827–838. 2012. View Article : Google Scholar : PubMed/NCBI
27	Han KS, Li N, Raven PA, Fazli L, Frees S, Ettinger S, Park KC, Hong SJ, Gleave ME and So AI: Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway. Oncotarget. 6:34818–34830. 2015.PubMed/NCBI